Smartkarma AI, Smartkarma

αSK

Smartkarma AI

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
 <li>
<a href="https://smartkarma.com/entities/puma-biotechnology-inc">Puma Biotechnology</a> is a single-product commercial-stage biopharmaceutical company, with its revenues entirely dependent on its sole approved product, NERLYNX (neratinib), for HER2-positive breast cancer.</li>
 <li>The company has achieved profitability and positive operating cash flow, shifting its focus to maximizing NERLYNX sales and advancing its key pipeline asset, alisertib, an Aurora Kinase A inhibitor, into Phase II trials for breast and small cell lung cancer.</li>
 <li>Significant long-term risk stems from intense competition in the HER2-positive breast cancer market from more effective therapies like AstraZeneca/Daiichi Sankyo's Enhertu, alongside the eventual patent expiration of NERLYNX in 2030.</li>
</ul>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


  
Puma Biotechnology is a single-product commercial-stage biopharmaceutical company, with its revenues entirely dependent on its sole approved product, NERLYNX (neratinib), for HER2-positive breast cancer.
  The company has achieved profitability and positive operating cash flow, shifting its focus to maximizing NERLYNX sales and advancing its key pipeline asset, alisertib, an Aurora Kinase A inhibitor, into Phase II trials for breast and small cell lung cancer.
  Significant long-term risk stems from intense competition in the HER2-positive breast cancer market from more effective therapies like AstraZeneca/Daiichi Sankyo's Enhertu, alongside the eventual patent expiration of NERLYNX in 2030.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Puma Biotechnology (PBYI US) - Oct 2025

Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Equity Capital Markets

JD Health International  / Equity Capital Markets

Healthcare’s presence in Asian capital markets has increased substantially over the last four years on the heels of substantial investments in private markets (VC/PE). Policy reforms and changes in listing rules, most notably in China, have led to an explosion of market cap creation for the sector as the universe of companies has expanded to include innovative companies, most notably pre-revenue biopharmaceutical companies. At the same time, substantial investments in digital healthcare, fueled by the COVID-19 pandemic, adds a new source of listed companies. This Insight focuses on leading unlisted healthcare companies in China, India, and ASEAN that have raised substantial amounts of capital and appear to be candidates for listing.

Healthcare’s presence in Asian capital markets has increased substantially over the last four years on the heels of substantial investments in private markets (VC/PE). Policy reforms and changes in listing rules, most notably in China, have led to an explosion of market cap creation for the sector as the universe of companies has expanded to include innovative companies, most notably pre-revenue biopharmaceutical companies. At the same time, substantial investments in digital healthcare, fueled by the COVID-19 pandemic, adds a new source of listed companies. This Insight focuses on leading unlisted healthcare companies in China, India, and ASEAN that have raised substantial amounts of capital and appear to be candidates for listing.   

United States

Puma Biotechnology, Inc. is a development-stage biopharmaceutical company. The Company develops novel therapeutics for the treatment of various forms of cancer. Puma focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Puma Biotechnology (PBYI US)

Primer: Puma Biotechnology (PBYI US) - Oct 2025

Puma Biotechnology is a single-product commercial-stage biopharmaceutical company, with its revenues entirely dependent on its sole approved...

αSK

Asian Healthcare - Coming of Age

This Smartkarma Originals Insight highlights 20 leading unlisted healthcare companies in Asia, mainly in digital healthcare and biopharma, that are...

Kemp Dolliver, CFA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)